ReviewOncoTargets and therapy2020

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.

Yazeed Sawalha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.